Australia markets close in 3 hours 43 minutes

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
176.09-1.24 (-0.70%)
At close: 04:00PM EST
175.55 -0.54 (-0.31%)
After hours: 07:57PM EST
Full screen
Trade prices are not sourced from all markets
Previous close177.33
Open177.01
Bid0.00 x 800
Ask0.00 x 900
Day's range174.66 - 177.26
52-week range155.72 - 186.69
Volume6,305,347
Avg. volume7,012,690
Market cap460.384B
Beta (5Y monthly)0.57
PE ratio (TTM)24.53
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield4.52 (2.55%)
Ex-dividend date21 Nov 2022
1y target estN/A
  • GlobeNewswire

    Purpose Investments Files Preliminary Prospectus for the First Yield-Focused Single-Stock ETFs

    TORONTO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (“Purpose Investments”) has filed and been receipted for a preliminary prospectus by the Canadian securities regulators in connection with the proposed launch of the first yield-focused single-stock ETFs (as outlined below) (collectively, the “ETFs” or “Purpose Yield Shares”). ETF NamesUnderlying Issuer Security Apple (AAPL) Yield SharesApple Inc.Common stockAmazon (AMZ) Yield SharesAmazon.com Inc.Common stockTesla (TSLA) Yield

  • Business Wire

    Johnson & Johnson to Acquire Abiomed

    NEW BRUNSWICK, N.J. & DANVERS, Mass., November 01, 2022--Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, and Abiomed (NASDAQ: ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender offer all outstanding shares of Abiomed, for an upfront payment of $380.00 per share in cash, corresponding to an

  • Business Wire

    Johnson & Johnson Reports Q3 2022 Results

    NEW BRUNSWICK, N.J., October 18, 2022--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2022. "Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses," said Joaquin Duato, Chief Executive Officer. "Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain con